CN104363916B - 用于治疗或预防肝病的用途的多孔碳颗粒 - Google Patents

用于治疗或预防肝病的用途的多孔碳颗粒 Download PDF

Info

Publication number
CN104363916B
CN104363916B CN201380025257.6A CN201380025257A CN104363916B CN 104363916 B CN104363916 B CN 104363916B CN 201380025257 A CN201380025257 A CN 201380025257A CN 104363916 B CN104363916 B CN 104363916B
Authority
CN
China
Prior art keywords
carbon
liver
particles
use according
porous carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380025257.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104363916A (zh
Inventor
卡罗尔·安吉拉·豪厄尔
谢尔盖·维克托维奇·米哈洛夫斯基
苏珊·雷切尔·桑德曼
拉吉夫·加兰
简·马克诺坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN104363916A publication Critical patent/CN104363916A/zh
Application granted granted Critical
Publication of CN104363916B publication Critical patent/CN104363916B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/16—Pore diameter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
CN201380025257.6A 2012-03-16 2013-03-15 用于治疗或预防肝病的用途的多孔碳颗粒 Active CN104363916B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1204696.7A GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy
GB1204696.7 2012-03-16
PCT/GB2013/050673 WO2013136094A1 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease

Publications (2)

Publication Number Publication Date
CN104363916A CN104363916A (zh) 2015-02-18
CN104363916B true CN104363916B (zh) 2018-09-25

Family

ID=46052080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380025257.6A Active CN104363916B (zh) 2012-03-16 2013-03-15 用于治疗或预防肝病的用途的多孔碳颗粒

Country Status (16)

Country Link
US (1) US9844568B2 (enExample)
EP (2) EP2825181B1 (enExample)
JP (2) JP6293680B2 (enExample)
KR (2) KR102441934B1 (enExample)
CN (1) CN104363916B (enExample)
AU (1) AU2013234099B2 (enExample)
BR (1) BR112014022810B1 (enExample)
DK (1) DK2825181T3 (enExample)
EA (1) EA038965B1 (enExample)
GB (1) GB201204696D0 (enExample)
IN (1) IN2014DN07637A (enExample)
MY (1) MY169093A (enExample)
NZ (1) NZ631429A (enExample)
SG (1) SG11201405771QA (enExample)
WO (1) WO2013136094A1 (enExample)
ZA (1) ZA201406989B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
ES2727153T3 (es) * 2014-04-17 2019-10-14 Immutrix Therapeutics Inc Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas
TWI607765B (zh) * 2014-08-27 2017-12-11 Kureha Corp Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
EP3476818A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved carbon source
EP3476817A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved amphiphilic species
WO2019131209A1 (ja) * 2017-12-27 2019-07-04 株式会社クラレ 活性炭およびその製法
JP7228498B2 (ja) * 2018-10-24 2023-02-24 フタムラ化学株式会社 フェノール樹脂の製造方法
WO2020085282A1 (ja) * 2018-10-24 2020-04-30 フタムラ化学株式会社 フェノール樹脂の製造方法
JP7338993B2 (ja) * 2019-03-06 2023-09-05 株式会社クラレ 多孔質炭素および多孔質炭素の製造方法
JP7061640B2 (ja) * 2019-04-16 2022-04-28 フタムラ化学株式会社 活性炭吸着剤の製造方法
WO2020213559A1 (ja) * 2019-04-16 2020-10-22 フタムラ化学株式会社 活性炭吸着剤の製造方法
JP7563145B2 (ja) * 2019-12-05 2024-10-08 ａｒｔｉｅｎｃｅ株式会社 多孔質炭素及びその製造方法
WO2024261472A1 (en) * 2023-06-20 2024-12-26 Yaqrit Limited Porous carbon particles for use in therapy
KR102971111B1 (ko) 2023-09-05 2026-06-02 한국생산기술연구원 열경화성 에폭시 조성물, 이의 경화물 및 용도
CN121925310A (zh) * 2025-03-28 2026-04-24 大阪燃气化学有限公司 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法
JP7724390B1 (ja) * 2025-03-28 2025-08-15 大阪ガスケミカル株式会社 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070363A1 (en) * 2009-12-09 2011-06-16 Mast Carbon International Ltd Carbon and its use in blood cleansing applications

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5332637B2 (enExample) * 1973-05-09 1978-09-09
JPS51151693A (en) 1975-06-23 1976-12-27 Eisai Co Ltd Coated bead-like activated carbon for blood purification
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
JPS5731864A (en) * 1980-08-04 1982-02-20 Teijin Ltd Oral activated carbon microcapsule
RU2177319C2 (ru) * 1999-03-30 2001-12-27 Российская медицинская академия последипломного образования МЗ РФ Способ лечения гиперэндотоксинемии
GB0019417D0 (en) 2000-08-09 2000-09-27 Mat & Separations Tech Int Ltd Mesoporous carbons
JP3522708B2 (ja) 2001-04-11 2004-04-26 呉羽化学工業株式会社 経口投与用吸着剤
JP4311923B2 (ja) * 2002-10-07 2009-08-12 株式会社クレハ 経口投与用肝疾患治療又は予防剤
EP1407772B9 (en) 2002-10-09 2007-02-21 Kureha Corporation Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases
CA2504517C (en) 2002-11-01 2008-08-12 Kureha Corporation Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2005089306A (ja) * 2003-09-12 2005-04-07 Ajinomoto Co Inc 炎症性腸疾患治療用の経直腸投与製剤
JP4382629B2 (ja) * 2003-10-22 2009-12-16 株式会社クレハ 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤
KR101135260B1 (ko) * 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
TWI370013B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP2007045775A (ja) 2005-08-11 2007-02-22 Japan Organo Co Ltd 含水活性炭及びその製造方法
DE102005062160A1 (de) 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CA2660883C (en) 2006-10-09 2014-12-09 British American Tobacco (Investments) Limited Carbonising and/or activating carbonaceous material
BRPI0719161A2 (pt) 2006-10-09 2014-02-04 British American Tobacco Co Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo.
WO2010138519A2 (en) 2009-05-27 2010-12-02 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of pruritus
PL2538930T3 (pl) 2010-02-23 2016-11-30 Preparaty do doustnego dostarczania środków adsorbujących do jelita
JP5984352B2 (ja) * 2010-10-12 2016-09-06 フタムラ化学株式会社 経口投与用医薬用吸着剤の製造方法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070363A1 (en) * 2009-12-09 2011-06-16 Mast Carbon International Ltd Carbon and its use in blood cleansing applications

Also Published As

Publication number Publication date
KR102441934B1 (ko) 2022-09-08
DK2825181T3 (da) 2020-04-14
IN2014DN07637A (enExample) 2015-05-15
EP2825181A1 (en) 2015-01-21
EP3650031B1 (en) 2026-07-01
MY169093A (en) 2019-02-18
EP2825181B1 (en) 2020-01-08
EA201491690A1 (ru) 2015-02-27
JP6647570B2 (ja) 2020-02-14
NZ631429A (en) 2016-09-30
EA038965B1 (ru) 2021-11-16
AU2013234099B2 (en) 2017-03-30
SG11201405771QA (en) 2014-10-30
JP6293680B2 (ja) 2018-03-14
KR20200096991A (ko) 2020-08-14
KR102142504B1 (ko) 2020-08-07
BR112014022810B1 (pt) 2021-04-13
AU2013234099A1 (en) 2014-10-02
KR20150002675A (ko) 2015-01-07
WO2013136094A1 (en) 2013-09-19
CN104363916A (zh) 2015-02-18
ZA201406989B (en) 2015-12-23
EP3650031A1 (en) 2020-05-13
EP3650031C0 (en) 2026-07-01
US20150064256A1 (en) 2015-03-05
US9844568B2 (en) 2017-12-19
JP2015516373A (ja) 2015-06-11
JP2018111699A (ja) 2018-07-19
GB201204696D0 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
JP6647570B2 (ja) 肝疾患の治療及び予防における使用のための多孔性炭素粒子
Zhao et al. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy
Ding et al. Oral colon-targeted konjac glucomannan hydrogel constructed through noncovalent cross-linking by cucurbit [8] uril for ulcerative colitis therapy
US9821024B2 (en) Immunomodulatory compositions
CN103841981B (zh) 口服给药用吸附剂
US8647666B2 (en) Administration of an adsorbent polymer for treatment of systemic inflammation
AU2021206871B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
CN113041232A (zh) 靶向肠道爆破的口服结肠靶向水凝胶及其制备方法与应用
Tan et al. Peritoneal air exposure elicits an intestinal inflammation resulting in postoperative ileus
Li et al. Risk assessment of silica nanoparticles on liver injury in metabolic syndrome mice induced by fructose
Yao et al. pH-responsive CuS/DSF/EL/PVP nanoplatform alleviates inflammatory bowel disease in mice via regulating gut immunity and microbiota
Hou et al. Integrated oral microgel system ameliorates renal fibrosis by hitchhiking co-delivery and targeted gut flora modulation
Wu et al. Astragaloside IV-loaded biomimetic nanoparticles target IκBα to regulate neutrophil extracellular trap formation for sepsis therapy
US20190142866A1 (en) Porous carbon particles for use in the treatment or prevention of liver disease
Wu et al. Inulin hydrogel loaded with self-assembled nanoparticles of curcumin and glycyrrhizic acid for inflammatory bowel disease treatment via anti-inflammation, antioxidation, and microbiota modulation
CN120114398B (zh) 多重响应结肠炎症靶向水凝胶微球及其制备方法和应用
WO2024261472A1 (en) Porous carbon particles for use in therapy
Niu et al. Antibacterial efficacy and pharmacokinetics of a poly (mPEG-b-PCEA)–trimethoprim conjugate
Sun Stimuli-Responsive Supramolecular Biomaterials for Targeted Treatment of Ulcerative Colitis
CN118717666B (zh) 一种载药丝素蛋白乳液及其制备方法与应用
Fatimah et al. The Beneficial Responses of Sodium Butyrate against DSS-Induced Colitis Mediated by Interleukin-10 Overexpression and Gut Microbiota in Rats
CN121927034A (zh) 一种用于治疗神经系统疾病的纳米胶囊及其制备方法和应用
CN121606707A (zh) 蛋白质-多酚涂层改性颗粒稳定的皮克林乳液及制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant